Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.18 USD | 0.00% | -10.61% | +105.22% |
Apr. 22 | Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating | MT |
Apr. 22 | Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+105.22% | 304M | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.13% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- OCGN Stock
- News Ocugen, Inc.
- Ocugen Doses First Patient in Phase 1/2 Trial of Gene Therapy to Treat Retinal Degeneration